Current and Future Directions in Glioblastoma Management - priME Oncology
Expert Perspectives
Expert Perspectives

Current and Future Directions in Glioblastoma Management

Incorporating New Strategies

Not a member of My prIME? Join now for instant access.

Hear insights on the optimal treatment approaches for patients with newly diagnosed and recurrent glioblastoma (GBM), with a focus on local therapy and immunotherapy. Faculty provide key points from their presentations, with downloadable slides available as a resource.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.25 AMA PRA Category 1 Credit™

Release Date

Release Date

Dec 22, 2017

Expiration Date

Dec 22, 2018

  • Maciej Mrugala, MD, PhD, MPHMayo Clinic
    Phoenix, Arizona, United States
  • Rimas Lukas, MDNorthwestern University
    Feinberg School of Medicine
    Chicago, Illinois, United States
  • David Reardon, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

Introduction
Maciej Mrugala, MD, PhD, MPH

A new look at local therapy in GBM
Rimas Lukas, MD

The impact of immunotherapy in GBM: Now and in the near term
David Reardon, MD

This educational activity is specifically designed to meet the needs of neuro-oncologists, medical oncologists, radiation oncologists, and other healthcare professionals providing care to patients with glioblastoma.

After successful completion of this educational activity, participants should be able to:

  • Select optimal therapy for patients diagnosed with GBM
  • Assess safety and efficacy data for new and emerging therapies for GBM

This educational activity is supported by a grant from Novocure.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Mrugala has disclosed receiving consulting fees from AbbVie and Novocure. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lukas has disclosed membership on advisory committees or review panels for AbbVie, AstraZeneca and Ziopharm. He also disclosed travel support from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Reardon has disclosed receiving consulting fees and honoraria for promotional speaker’s bureaus from AbbVie, Agenus, Amgen, Bristol-Myers Squibb, Cavion, Celldex Therapeutics, EMD Serono, Genentech/Roche, Inovio, Juno Pharmaceuticals, Merck, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Oxigene, Regeneron, and Stemline Therapeutics. He has also disclosed independent contracting for Acerta Pharm, Agenus, Celldex Therapeutics, EMD Serono, Incyte, Inovio, Midatech, and Tragara. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.